Medications | National Headache Foundation

Headache Medicine Certification Exam Deadline is August 23

August 4, 2022

Practitioners Who Care for Patients with Migraine Diseases and Headache Disorders Should Review Updated Qualifications and Register Soon The National Headache Foundation (NHF) announced its Fall certification exam for its Certificate of Added Qualification in Headache Medicine (AQH) program….

Heads UP – Episode 126: Migraine Medication Failures

June 13, 2022

Have you had a migraine medication fail you? Or have multiple migraine medications failed you? How did it make you feel? In this episode of Heads UP Lindsay Weitzel, Ph.D. talks to Melissa Geraghty Psy.D. about how this makes us…

Evaluating Chronic Migraine Medication Overuse Strategies

May 5, 2022

Neurology Live April 30, 2022 Marco Meglio Vincent Martin, MD, president of the National Headache Foundation, discussed the MOTS trial, a non-inferiority study aimed at understanding treatment strategies with preventives for chronic migraine. Vincent Martin, MD The Medication Overuse Treatment…

Heads UP – Episode 118: Medication Overuse Treatment Strategy Trial for Migraine and Headache

April 11, 2022

Heads UP – Episode 118: Medication Overuse Treatment Strategy Trial -The idea of medication overuse and medication overuse headache can seem almost contradictory at times. It can seem like the very medicines we were instructed to take at the onset…

Heads UP – Episode 116: Treating Migraine With Infusions

March 21, 2022

Heads UP – Episode 116: Treating Migraine With Infusions – In this week’s episode of Heads UP Lindsay Weitzel, Ph.D. discusses infusions with Dr. Merle Diamond, MD. What infusions are used to break a migraine cycle and why? What medicines…

Heads UP Audio Podcast: Low-Pressure Headache – Finding the Leak

March 9, 2022

Heads UP: Low-Pressure Headache – Finding the Leak Do you know the symptoms of low-pressure headache or spontaneous intracranial hypotension (SIH)? Often it presents with a chronic headache that is better when you lie down and worse when you sit…

Allow Migraine Patients and Primary Care Providers to Set Care Plans – NOT INSURERS

February 11, 2022

Add your name to the NHF’s petition if you agree that insurance companies should adopt care models that are patient-centric, where the clinician, in collaboration with the patient, is the primary decision-maker and selects a treatment that addresses the patient’s…

Heads UP – Episode 112: Access to Care

February 9, 2022

For too long, migraine patients have been treated differently than others with medical issues as it relates to access to prescription medications. The National Headache Foundation advocates that payers adopt care models that are patient-centric, where the clinician, in…

NHF Calls on Congress and Federal Agencies to Conduct Oversight Of Current Care Models for Migraine Patients

February 3, 2022

Chicago, Ill. (Feb. 3, 2022) – Tom Dabertin, Chief Executive Officer/Executive Director of the National Headache Foundation (NHF) is calling on members of Congress and regulatory agencies to conduct oversight of health insurance payers for uneven treatment of migraine patients. On…

National Headache Foundation Position Statement on the Treatment of Migraine and Access to Care

January 19, 2022

January 19, 2022 For more than 52 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine. For too long, migraine patients have been treated differently than others with medical…

NHF Challenges Current Care Models for Migraine Patients

January 19, 2022

Older Prescription Drugs in a Stepwise Approach Needs Health Insurance Overhaul Chicago, Ill. (Jan. 19, 2022) – The National Headache Foundation issued a statement challenging health insurance payers for uneven treatment of migraine patients, arguing “current care models have not…

Heads UP – Episode 109: DATA Alert on Intranasal Zavegepant

January 10, 2022

New Data Alert on the Up-and-Coming Migraine Medication: Intranasal Zavegepant. While not yet approved for release, intranasal zavegepant has shown promise in some interesting and unique data points in the relief of acute migraine. What is zavegepant and what will…

Next ›